Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

U.S. Economic Crisis, Beijing’s Perks, Could Trigger Reverse Brain Drain

This article was originally published in PharmAsia News

Executive Summary

BEIJING - The financial meltdown and widening layoffs in the United States, combined with Beijing's injection of stimulus funds into its pharmaceutical and biotech sectors, could trigger a reverse brain drain in those sectors, according to industry insiders and investors in the U.S. and China

You may also be interested in...



China Will Seize Ranking As Globe's Top Innovative Center From U.S. By 2020: AstraZeneca Survey

BEIJING - A survey commissioned by British-headquartered AstraZeneca that polled public perceptions across three continents - Europe, North America and Asia -predicts that China will dethrone the United States to become the globe's most innovative center by 2020

China Will Seize Ranking As Globe's Top Innovative Center From U.S. By 2020: AstraZeneca Survey

BEIJING - A survey commissioned by British-headquartered AstraZeneca that polled public perceptions across three continents - Europe, North America and Asia -predicts that China will dethrone the United States to become the globe's most innovative center by 2020

San Francisco Aims To Become Primary Gateway For Chinese Biotech Firms Expanding Across Pacific

BEIJING - San Francisco is stepping up its drive to become the North American headquarters for Chinese enterprises expanding across the Pacific and to attract life science firms based in the People's Republic to the Bay Area

Related Content

UsernamePublicRestriction

Register

LL1123738

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel